The current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...

Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...

The efforts over the past year by the team at Keros have positioned us to continue to advance our promising pipeline of novel therapeutics,” said Jasbir S. Seehra, Ph.D., Chair and Chief Executive ...

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...

Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in ...

Zurich: Takeda has announced that the European Medicines Agency (EMA) has given approval for an additional 2 mL pre-filled ...

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

This year's Fujisankei Ladies Classic golf tournament, scheduled for April 25-27 in Shizuoka Prefecture, will be canceled, Japan LPGA Tour sources said Wednesday. Main tournament sponsor Fuji ...